1. Home
  2. THRD vs CYD Comparison

THRD vs CYD Comparison

Compare THRD & CYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THRD
  • CYD
  • Stock Information
  • Founded
  • THRD 2019
  • CYD 1951
  • Country
  • THRD United States
  • CYD Singapore
  • Employees
  • THRD N/A
  • CYD N/A
  • Industry
  • THRD Biotechnology: Pharmaceutical Preparations
  • CYD Industrial Machinery/Components
  • Sector
  • THRD Health Care
  • CYD Industrials
  • Exchange
  • THRD Nasdaq
  • CYD Nasdaq
  • Market Cap
  • THRD 513.2M
  • CYD 493.2M
  • IPO Year
  • THRD 2022
  • CYD 1994
  • Fundamental
  • Price
  • THRD $11.45
  • CYD $9.42
  • Analyst Decision
  • THRD Strong Buy
  • CYD
  • Analyst Count
  • THRD 3
  • CYD 0
  • Target Price
  • THRD $20.33
  • CYD N/A
  • AVG Volume (30 Days)
  • THRD 218.2K
  • CYD 18.9K
  • Earning Date
  • THRD 11-07-2024
  • CYD 08-12-2024
  • Dividend Yield
  • THRD N/A
  • CYD 4.14%
  • EPS Growth
  • THRD N/A
  • CYD 14.53
  • EPS
  • THRD N/A
  • CYD 1.17
  • Revenue
  • THRD N/A
  • CYD $2,639,608,357.00
  • Revenue This Year
  • THRD N/A
  • CYD $11.68
  • Revenue Next Year
  • THRD N/A
  • CYD $4.06
  • P/E Ratio
  • THRD N/A
  • CYD $7.82
  • Revenue Growth
  • THRD N/A
  • CYD 15.32
  • 52 Week Low
  • THRD $7.08
  • CYD $7.85
  • 52 Week High
  • THRD $16.94
  • CYD $13.05
  • Technical
  • Relative Strength Index (RSI)
  • THRD 40.06
  • CYD 28.75
  • Support Level
  • THRD $10.10
  • CYD $8.91
  • Resistance Level
  • THRD $12.49
  • CYD $9.55
  • Average True Range (ATR)
  • THRD 1.30
  • CYD 0.45
  • MACD
  • THRD -0.32
  • CYD -0.09
  • Stochastic Oscillator
  • THRD 25.00
  • CYD 17.86

About THRD Third Harmonic Bio Inc.

Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

About CYD China Yuchai International Limited

China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International primarily operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.

Share on Social Networks: